Supplementary Data from A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

Adi Diab,Omid Hamid,John A. Thompson,Willeke Ros,Ferry A.L.M. Eskens,Toshihiko Doi,Siwen Hu-Lieskovan, Samuel J. Klempner,Bishu Ganguly,Catherine Fleener,Xiao Wang,Tenshang Joh,Ken Liao,Shahram Salek-Ardakani,Carrie Turich Taylor,Jeffrey Chou,Anthony B. El-Khoueiry

crossref（2023）

引用 0|浏览18

暂无评分

摘要

Supplementary Data from A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要